Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase II Study of AK104 in the Treatment of Recurrent or Metastatic Vulvar Cancer

NCT05932212 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT05932212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05932212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase II Study of AK104 in the Treatment of Recurrent or Metastatic Vulvar Cancer
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Terminated
Start date
August 25, 2023
Completion date
May 31, 2026
Enrollment
20 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

vulvar cancer